预约演示

Prothena mulling sale ahead of key Alzheimer's drug data: report

2023-10-16

交易

临床1期引进/卖出抗体药物偶联物

Prothena is getting ready to weigh strategic options that may include a sale or partnership, according to a Bloomberg report Monday citing people familiar with the matter. Company shares jumped roughly 23% on the news, giving it a market value of about $2.9 billion.

Prothena is working on a closely-watched anti-amyloid beta antibody for Alzheimer's disease, with the rumours surfacing ahead of key data on the drug expected in the coming months. Prothena's portfolio includes PRX012, a next-generation subcutaneously delivered anti-amyloid beta antibody, currently in an ongoing Phase I study for the treatment of Alzheimer's disease.

According to Monday's Bloomberg report, sources said Prothena would likely attract interest from large drugmakers if it decides to move forward with a potential sale or tie-up. The report noted that deliberations are still in the early stages, and Prothena could decide to remain independent for longer, particularly if the data due later this year turn out to be negative.

Meanwhile, Bristol Myers Squibb recently exercised an option to obtain exclusive worldwide commercial rights to Prothena's anti-tau antibody PRX005. The option stems from a 2018 deal potentially worth up to $2.2 billion between Prothena and Celgene, which Bristol Myers Squibb acquired a few years ago.

Eisai is also developing a subcutaneous version of its Biogen-partnered Alzheimer's drug Leqembi (lecanemab), while Eli Lilly's Alzheimer's disease drug candidate donanemab is under US regulatory review.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构

Prothena Corp. Plc